IL-2-TNFα融合基因与B7.1基因联合修饰的肿瘤的疫苗作用  

The Vaccine Effect of Tumor Cells Co-modified by IL-2-TNFα Fusion Gene and B7.1 Gene

作　　者：刘雪丰[1] 张连峰[1] 张铭[1] 马耀文[1] 蔡有余[1] 

机构地区：[1]中国协和医科大学中国医学科学院实验动物研究所,北京100021

出　　处：《中国实验动物学报》2000年第2期98-106,共9页Acta Laboratorium Animalis Scientia Sinica

摘　　要：目的　改进基因修饰的肿瘤细胞疫苗的效力。方法　在小鼠乳腺癌细胞系EMF6 和一个已被含有IL - 2和TNFα融合基因的逆转录病毒载体XdF转染的EMF6 亚系 (T2 -EMF6)中表达B7 1基因。结果　免疫 /侵袭实验表明 ,与单基因转导的肿瘤细胞相比 ,IL - 2-TNFα/B7 1共同修饰的肿瘤细胞具有较低的致瘤性和较优的疫苗效力 (P <0 0 5)。在各种肿瘤细胞的免疫接种后三周 ,进行混合淋巴细胞培养实验和51 Cr释放实验来检测动物的细胞免疫活性 ,IL - 2 -TNFα和B7 1共同作用诱导了比其中的任意一个单独作用更强的抗肿瘤应答 (比IL - 2 -TNFα高 2 5% ,比B7 1高 2 0 % )。结论　IL - 2 -TNFα和B7 1协同作用可提高他们所修饰的肿瘤细胞的疫苗效力。Objectire To improve the vaccine potency of gene-modified tumor cells Methods Using recombinant adenoviruses,we expressed the B7.1 gene in murine breast tumor cell line EMF 6 and a subline previously transfected with retrovirus vector XdF containing IL-2-TNFα fusion gene. Rescults Immunization/challenge experiments demonstrated that IL-2-TNFα/B7.1 co-modified tumor cells possessed a lower tumorigenicity in vivo and an improved tumor-specific vaccine potency when compared to single gene transfectant(P<0.05). Three weeks after immunization with a variety of tumor cells,mixed lymphocyte culture assay and 51 Cr-release assay were performed to test the cellular immunity activities. The results indicated that IL-2-TNFα and B7.1 together induced a more potent antitumor immune response compared to either molecule alone (25% and 20% higher than IL-2-TNFα and B7.1 respectively). Conclusion Our results suggest that an improved tumor cell vaccine efficacy can be acquired by the concerted action of IL-2-TNFα and B7.1.

关 键 词：B7.1 IL-2 TNF 肿瘤细胞 疫苗效力 融合基因 联合 免疫接种 动物 释放 

分 类 号：Q785[生物学—分子生物学] R733[医药卫生—肿瘤]